Loading stock data…
Sionna Therapeutics, Inc. (SION)
$42.97+0.79 (+1.87%)
Market ClosedLast close Jun 29
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sionna Therapeutics, Inc. in the Healthcare sector is trading at $42.97 with a market capitalization of $1.7B. Wall Street consensus targets $51.60 (10 analysts), implying a +20.1% move over the next 12 months. The stock is currently near its 52-week high of $48.45, remaining 13.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.60M↓ | -$23.61M↑ | -$23.80M↓ | -$21.91M↓ | -$19.66M |
| Net Income | -$26.78M↓ | -$20.44M↓ | -$20.28M↓ | -$18.07M↓ | -$16.48M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmemb...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.69%
Volume
Today's trading volume
304,059
Recent News
Assessing Sionna Therapeutics (SION) Valuation After A Mixed Period For Recent Share Price Returns
Event overview and recent stock performance Sionna Therapeutics (SION) stock has been drawing attention after recent trading, with the share price closing at US$34.03 and returns mixed over different periods, including a gain over the past year. See our latest analysis for Sionna Therapeutics. While the 1-year total shareholder return of 97.16% points to strong longer term gains, the share price has recently cooled, with the 30-day share price return down 25.94% and the year-to-date share...
Wedbush Initiates Coverage of Sionna Therapeutics (SION)
Sionna Therapeutics, Inc. (NASDAQ:SION) is one of the best small cap stocks to buy for 10x potential. Wedbush initiated coverage of Sionna Therapeutics, Inc. (NASDAQ:SION) with an Outperform rating on May 4, setting a price target of $53. The firm told investors in a research note that the company is continually focusing on the development […]
A Look At Sionna Therapeutics (SION) Valuation After Its Strong 1 Year Return And Premium P/B Ratio
What Sionna Therapeutics Stock Data Suggests Right Now Sionna Therapeutics (SION) has drawn investor attention after a very large 1 year total return of 216.26%, alongside mixed shorter term moves including a roughly flat month and a 9.06% decline over the past 3 months. See our latest analysis for Sionna Therapeutics. Recent trading shows momentum cooling, with a 1-year total shareholder return of 216.26% contrasted by a 90-day share price return of a 9.06% decline from the latest share...
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch
This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance.
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story
This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings.